HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Benjamin Noll Selected Research

Cyclin D1

12/2020A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Benjamin Noll Research Topics

Disease

6Neoplasms (Cancer)
02/2023 - 01/2017
2Retinoblastoma (Glioblastoma, Retinal)
12/2020 - 01/2018
1Body Weight Changes
02/2023
1Leukemia
02/2022
1Ovarian Neoplasms (Ovarian Cancer)
12/2020
1Body Weight (Weight, Body)
01/2017
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2017

Drug/Important Bio-Agent (IBA)

2Proteins (Proteins, Gene)FDA Link
02/2022 - 01/2018
2Cyclin DIBA
12/2020 - 01/2018
1Rilpivirine (TMC-278)IBA
02/2023
1Aurora Kinase AIBA
02/2023
1acivicin (AT 125)IBA
02/2022
1Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2020
1Cyclin-Dependent Kinases (cdk Proteins)IBA
12/2020
1Cyclin D1IBA
12/2020
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2020
1EverolimusFDA Link
12/2020
1Peptide Initiation Factors (Initiation Factor)IBA
01/2019
1Eukaryotic Initiation Factor-4EIBA
01/2019
1Phosphotransferases (Kinase)IBA
01/2018

Therapy/Procedure

2Oral Administration
02/2022 - 01/2017
2Therapeutics
12/2020 - 01/2018